相关实验视频
Updated: May 28, 2025

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
43.6K
阿尔德脱酶2基因多态性和尼特洛甘油对冠状动脉的血管扩张作用之间的关系
Kai Zhang1, Chi He2, Yaliang Tong3
1Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Journal of cardiovascular pharmacology
|February 10, 2025
概括
化脱酶2 (ALDH2) 基因变异会影响冠状动脉对酸甘的反应. ALDH2多态性影响血液动力学变化和动脉扩张,影响心痛患者的治疗有效性.
科学领域:
- 心脏病学 心脏病学
- 药物基因组学 药物基因组学
- 遗传学 遗传学 是一个
背景情况:
- 化脱酶2 (ALDH2) 对于酸甘油的代谢至关重要.
- 对于ALDH2基因多态化与冠状动脉血管扩张对尼甘的反应之间的关系尚不清楚.
研究的目的:
- 为了研究ALDH2基因多态性 (Glu504Lys) 与冠状动脉血管扩张在冠状动脉内尼特糖氨酸给药后之间的关联.
- 评估ALDH2变异对血液动力学参数和冠状动脉直径变化的影响.
主要方法:
- 427名怀疑患有胸痛的患者接受了ALDH2基因定型.
- 在冠状动脉血管造影期间,进行了冠状动脉内酸盐 (200微克) 的注射.
- 血液动力学参数 (SBP,DBP,HR) 和冠状动脉直径 (参考和狭窄) 被测量.
主要成果:
- 野生类型和突变ALDH2组都显示出尼糖后显著的血液动力学变化.
- 野生类型的组有较大降低缩血压.
- 突变型组与野生型组相比,对参考冠状动脉直径的变化较小.
结论:
- ALDH2基因多态性 (Glu504Lys) 与改变对酸甘的血液动力学反应有关.
- ALDH2变种影响了尼特甘药后冠状动脉血管扩张的程度.
相关概念视频
Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K
Antihypertensive Drugs: Vasodilators
462
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
462
Antianginal Drugs: Nitrates and β-Blockers
507
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
507
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
460
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
460
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
446
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
446

